Merck, Eisai notch full approval for Keytruda-TKI inhibitor combo in advanced endometrial cancer
Merck PD-1 inhibitor Keytruda has been in the hot seat as the FDA rifles through its accelerated approval program for drugs that eventually flop confirmatory …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.